|[July 02, 2014]
Mazor Robotics Reports Orders for Four Renaissance Systems During the Second Quarter of 2014
CAESAREA, Israel --(Business Wire)--
Mazor Robotics Ltd. (TASE:MZOR; NASDAQ GM:MZOR), a developer of
innovative guidance systems and complementary products, announced today
that it received orders for and delivered four Renaissance systems, two
in the U.S. and two in international markets, in the second quarter
which ended June 30, 2014. Of the four systems, one included the
recently launched brain surgery module.
Today's announcement was made in accordance with Mazor Robotics'
disclosure policy of announcing the total number of Renaissance systems
orders in the quarter immediately after the end of the quarter. Mazor
Robotics will announce the second quarter financial results in early
"Interest on the part of surgeons to acquire the Renaissance system
reached all time highs, and clinical results from the use of our system
continue to be outstanding. As a result, our system order pipeline
remains strong," said Ori Hadomi, CEO of Mazor Robotics. "The first U.S.
commercial order of our recently released brain surgery module from a
new customer as part of its Renaissance installation represents a new
milestone for Mazor. The brain application is gaining interest with new
and existing customers. During the quarter we faced extended
administrative approval processes for system orders by additional
potential customers. We currently expect these additional system orders
to be concluded during the second half of the year."
Mazor Robotics is dedicated to the development andmarketing of
innovative surgical guidance systems and complementary products that
provide a safer surgical environment for patients, surgeons, and
operating room staff. Mazor Robotics' flagship product, Renaissance®, is
a state-of-the-art surgical guidance system that enables surgeons to
conduct spine surgeries in an accurate and secure manner. Mazor Robotics
systems have been successfully used in the placement of over 45,000
implants worldwide. Numerous peer-reviewed publications and
presentations at leading scientific conferences have validated the
accuracy, usability, and clinical advantages of Mazor Robotics
technology. For more information, the content of which is not part of
this press release, please visit www.mazorrobotics.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
other securities laws. Any statements in this release about future
expectations, plans or prospects for the Company, including without
limitation, statements regarding interest on the part of surgeons to
acquire the Renaissance system continuing to reach all time highs, that
our system order pipeline remains strong, that the brain application is
gaining interest with new and existing customers, and that system sales
by additional potential customers are expected to conclude beyond
quarter end, and other statements containing the words "believes,"
"anticipates," "plans," "expects," "will" and similar expressions are
forward-looking statements. These statements are only predictions based
on Mazor's current expectations and projections about future events.
There are important factors that could cause Mazor's actual results,
level of activity, performance or achievements to differ materially from
the results, level of activity, performance or achievements expressed or
implied by the forward-looking statements. Those factors include, but
are not limited to, the impact of general economic conditions,
competitive products, product demand and market acceptance risks,
reliance on key strategic alliances, fluctuations in operating results,
and other factors indicated in Mazor's filings with the Securities and
Exchange Commission (SEC (News - Alert)) including those discussed under the heading
"Risk Factors" in Mazor's annual report on Form 20-F filed with the SEC
on April 9, 2014 and in subsequent filings with the SEC. For more
details, refer to Mazor's SEC filings. Mazor undertakes no obligation to
update forward-looking statements to reflect subsequent occurring events
or circumstances, or to changes in our expectations, except as may be
required by law.
[ Back To TMCnet.com's Homepage ]